Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Blood Advances|November 4, 2020
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphomaMarcelo C Pasquini, Zhen-Huan Hu, Kevin Curran, et al.
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.
Blood|March 18, 2021
A rapid genotyping panel for detection of primary central nervous system lymphomaMihir Gupta, Evan J Burns, Nicholas Z Georgantas, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Blood|May 23, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesMatthew J Frigault, Charlotte E Graham, Trisha R Berger, et al.
Transplantation and Cellular Therapy|October 9, 2025
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>Melissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Transplantation and Cellular Therapy|March 11, 2023
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeMelissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Blood Advances|November 4, 2020
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphomaMarcelo C Pasquini, Zhen-Huan Hu, Kevin Curran, et al.
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.
Blood|March 18, 2021
A rapid genotyping panel for detection of primary central nervous system lymphomaMihir Gupta, Evan J Burns, Nicholas Z Georgantas, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Blood|May 23, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesMatthew J Frigault, Charlotte E Graham, Trisha R Berger, et al.
Transplantation and Cellular Therapy|October 9, 2025
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>Melissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Transplantation and Cellular Therapy|March 11, 2023
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeMelissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Pageof 12